TLR2 and breast carcinoma: Propranolol, a β-adrenergic signaling antagonist, demonstrates palliative effects on breast cancer progression and survival, primarily through TLR2-directed immunomodulation, such as altering the polarization of macrophages, and increasing the activation of cytotoxic T cells and NK cells (52).